Russell Investments Group Ltd. Purchases 16,825 Shares of argenex SE $ARGX

Russell Investments Group Ltd. increased its holdings in argenex SE (NASDAQ:ARGX – Free Report) by 176.4% during the 3rd quarter, Holdings Channel reports. The firm owned 26,365 shares of the company’s stock after buying an additional 16,825 shares during the period. Russell Investments Group Ltd.’s holdings in argenex were worth $25,284,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Eastern Bank bought a new position in argenex during the 2nd quarter valued at approximately $32,000. Axiom Investment Management LLC purchased a new stake in argenex in the 1st quarter worth approximately $50,000. Richardson Financial Services Inc. bought a new stake in shares of argenex in the 3rd quarter worth approximately $66,000. Mather Group LLC. grew its position in shares of argenex by 19.1% in the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after buying an additional 13 shares during the last quarter. Finally, Provenance Wealth Advisors LLC bought a new stake in shares of argenex in the 3rd quarter worth approximately $84,000. 60.32% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ARGX has been the topic of several research analyst reports. Oppenheimer reduced their target price on argenex from $1,100.00 to $1,038.00 and set an “outperform” rating on the stock in a research note on Monday, October 12th. Wedbush dropped their price target on argenex from $1,150.00 to $1,130.00 and set an “outperform” rating for the company in a research note on Thursday, October 8th. Guggenheim dropped their price target on argenex from $1,185.00 to $1,120.00 and set a “buy” rating for the company in a research note on Friday, October 23rd. HC Wainwright lifted their price target on shares of argenex from $940.00 to $1,202.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of argenex in a research report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,163.18.

Check Out Our Latest Stock Report on argenex

argenex Price Performance

ARGX stock opened at $947.52 on Wednesday. argenex SE has a 1 year low of $661.85 and a 1 year high of $1,072.75. The company has a market cap of $59.59 billion, a P/E ratio of 33.06, a PEG ratio of 0.88 and a beta of 0.48. The firm has a 50-day moving average of $921.04 and a 200 day moving average of $861.80.

argenex (NASDAQ:ARGX – Get Free Report) last issued its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping the consensus estimate of $7.44 by $0.36. The business had revenue of $1.75 billion during the quarter. argenex had a net margin of 31.66% and a return on equity of 47.70%. On average, equities research analysts expect that argenex SE will post 28.41 earnings per share for the current fiscal year.

About argenex

(Free Report)

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.

See Also

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).

Institutional Ownership by Quarter for argenex (NASDAQ:ARGX)

Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.